Challenges and opportunities for improving access to approved neonatal drugs and devices

TLDR: In this paper , the authors argue that neonatal drug and device development has lagged behind other patient populations and that providers are using drugs and devices without adequate study of safety and efficacy, which will require novel approaches and unique collaborations between multiple key stakeholders.

Abstract: Neonatal drug and device development has lagged behind other patient populations. Oftentimes, providers are using drugs and devices without adequate study of safety and efficacy. Neonates deserve dedicated drug and device development programs, which will require novel approaches and unique collaborations between multiple key stakeholders. Legislative efforts, infrastructure, clinical trial methodology, and international collaborations have all contributed to improvements in neonatal drug and device development, but more work is still needed. Leadership from neonatologists, clinical care providers, and parents is essential to implement needed changes.